Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Multimedia Psychoeducation or Print Education in Preparing Cancer Patients for Decision Making About Clinical Trials

25 de janeiro de 2021 atualizado por: Gary Morrow

Evaluation of Psychoeducation for Cancer Patients Eligible for Clinical Trials

This randomized clinical trial compares multimedia psychoeducation to print education in preparing patients with cancer for decision making about clinical trial participation. Multimedia psychoeducation includes a digital video disc (DVD) and written materials with a combined focus on knowledge and attitude change, and may be an effective method to help patients prepare for decision making about clinical trial participation. It is not yet known whether a multimedia psychoeducation is more effective than print education in preparing patients for decision making about clinical trials.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVES:

I. To determine the effect of intervention assignment on patients' preparedness for decision making about clinical trial participation.

SECONDARY OBJECTIVES:

I. To determine the effect of intervention assignment on indicators of the quality of patients' decision making about clinical trial participation.

II. To examine mechanisms by which multimedia psychoeducation (MP) exerts its expected positive effects on preparedness for decision making.

TERTIARY OBJECTIVES:

I. To explore the effects of intervention assignment on clinical trial participation.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the National Cancer Institute (NCI) booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.

ARM II: Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a digital video disk (DVD) and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.

After completion of study, patients are followed up at 3-7 and 49-56 days.

Tipo de estudo

Intervencional

Inscrição (Real)

418

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • San Diego, California, Estados Unidos, 92182
        • San Diego State University
    • Florida
      • Tampa, Florida, Estados Unidos, 33612
        • H. Lee Moffitt Cancer Center and Research Institute
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Hawaii MU-NCORP
    • Illinois
      • Decatur, Illinois, Estados Unidos, 62526
        • Heartland NCORP
    • Kansas
      • Prairie Village, Kansas, Estados Unidos, 66208
        • Kansas City Clinical Oncology Program
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Gulf South MU-NCORP
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Cancer Research Consortium of West Michigan
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55426
        • Metro MN NCORP
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89106
        • Nevada Cancer Research Foundation NCORP
      • Las Vegas, Nevada, Estados Unidos, 89106
        • Nevada NCORP
    • New York
      • Rochester, New York, Estados Unidos, 14642
        • URCC / University of Rochester NCORP Research Base
    • North Carolina
      • Winston-Salem, North Carolina, Estados Unidos, 27104
        • Southeast Clinical Oncology Research Consortium
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43215
        • Columbus NCORP
      • Dayton, Ohio, Estados Unidos, 45420
        • Dayton Community Oncology Program
    • Pennsylvania
      • Danville, Pennsylvania, Estados Unidos, 17822
        • Geisinger Cancer Institute NCORP
    • South Carolina
      • Greenville, South Carolina, Estados Unidos, 29615
        • Greenville Health System Cancer Instutite/Greenville NCORP
    • Wisconsin
      • Marshfield, Wisconsin, Estados Unidos, 54449
        • Wisconsin NCORP
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Aurora NCORP

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Be able to speak and read English
  • Be diagnosed with cancer
  • Have been informed of their eligibility for a specific phase II or III therapeutic clinical trial open for enrollment at the participating NCI Community Oncology Research Program (NCORP) site
  • Have already met one or more eligibility criteria and have a reasonable expectation of meeting any remaining eligibility criteria for the therapeutic clinical trial
  • Be capable of providing written informed consent for study participation

Exclusion Criteria:

  • Participants must not have been asked previously to participate in another therapeutic cancer clinical trial
  • Participants must not have already made a decision to participate in the phase II or III therapeutic clinical trial for which they were informed of their eligibility
  • Participants must not have documented or observable visual, auditory, psychiatric, or neurological disorders that would interfere with study participation (e.g., blindness, deafness, psychosis, or dementia)
  • Participants must not be eligible only for phase I trial; these patients are excluded because few of these trials are offered at NCORP sites and because their design and goals differ considerably from those of phase II and III trials

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm I (print educational)
Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.
print educational intervention
Outros nomes:
  • intervenção, educacional
Experimental: Arm II (multimedia psychoeducational)
Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.
multimedia psychoeducational intervention
Outros nomes:
  • intervenção, educacional

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Preparedness for Decision Making About Clinical Trial Participation, Measured Using Scores From the Preparation for Decision Making Scale
Prazo: Day 3 to 7
Preparation for Decision Making Scale (PDMS) is a valid and reliable 10-item self-report measure for which respondents rate the usefulness of materials they were provided in preparing them to communicate with their health care provider and make a health care decision. Each item is scored 1 to 5 where 1=Not at All, 2=A Little, 3=Somewhat, 4=Quite a Bit, 5=A Great Deal. Larger number is better. All 10 scores are summed, then divided by 10; The result - 1 is then multiplied by 25 and we have a range from 0 (less prepared) - 100 (most prepared).
Day 3 to 7

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
The Decision Regret Scale (DRS)
Prazo: Day 49-56
The Decision Regret Scale (DRS) is a five-item paper and pencil self-report measure that asks subjects to reflect on a particular decision and then rate each item on a Likert scale from 1 (strongly agree) to 5 (strongly disagree). A mean score for the DRS is calculated by reverse scoring the two negatively phrased items and dividing by five. The mean scores are converted to a score ranging from 0 to 100 by subtracting 1 and multiplying by 25 and higher scores represent increases in the severity of decision regret. Higher scores are worse.
Day 49-56
The Decisional Conflict Scale (DCS)
Prazo: Day 49-56
The Decisional Conflict Scale (DCS) is a valid and reliable 16-item self-report measure that assesses the extent to which respondents experience certainty, satisfaction, and confidence following a health care decision. In the present study, it will be keyed to the decision about therapeutic clinical trial participation. Instructions given to respondents include asking them to reflect on the decisions have just made or are about to make and to respond to statements in the DCS using a five-point Likert scale. Responses to each statement are scored from 1 (strongly agree) to 5 (strongly disagree), with negative statements having reverse scoring; thus high scores indicate higher decisional conflict.
Day 49-56

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
To Explore the Effects of Intervention Assignment on Clinical Trial Participation.
Prazo: Day 49-56
Given the ethical perspective that patients have a right to make autonomous decisions about clinical trial participation, no hypothesis is offered about the effect of intervention assignment on clinical trial participation rates. To conduct the exploratory analysis regarding the effects of intervention assignment on clinical trial participation, data for all patients offered participation in a therapeutic clinical trial will be entered into a 2 (Intervention: MP or PE) x 2 (Clinical Trial Participation: Yes or No/Still Deciding) contingency table and analyzed using either a Fisher exact test or chi-square test as appropriate.
Day 49-56

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Paul Jacobsen, University of Rochester

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de maio de 2014

Conclusão Primária (Real)

31 de agosto de 2016

Conclusão do estudo (Real)

1 de novembro de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

31 de janeiro de 2014

Enviado pela primeira vez que atendeu aos critérios de CQ

31 de janeiro de 2014

Primeira postagem (Estimativa)

4 de fevereiro de 2014

Atualizações de registro de estudo

Última Atualização Postada (Real)

27 de janeiro de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de janeiro de 2021

Última verificação

1 de janeiro de 2021

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • URCC12107 (Outro identificador: University of Rochester)
  • U10CA037420 (Concessão/Contrato do NIH dos EUA)
  • NCI-2013-02237 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • URCC-12107 (Outro identificador: DCP)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever